Research Progress of Clonal Hematopoiesis of Indeterminate Potential in Multiple Myeloma --Review.
10.19746/j.cnki.issn.1009-2137.2022.02.049
- Author:
Lin-Zi LEI
1
;
Yao-Mei WANG
1
;
Bai-Jun FANG
2
Author Information
1. Department of Hematology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, Henan Province, China.
2. Department of Hematology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, Henan Province, China,E-mail: fdation@126.com.
- Publication Type:Review
- Keywords:
cardiovascular disease;
clonal hematopoiesis;
lenalidomide;
multiple myeloma;
treatment
- MeSH:
Clonal Hematopoiesis;
Hematopoiesis;
Humans;
Multiple Myeloma;
Mutation;
Myelodysplastic Syndromes
- From:
Journal of Experimental Hematology
2022;30(2):618-621
- CountryChina
- Language:Chinese
-
Abstract:
With the progress of medical technology, cloning hematopoietic was found to be widely exist in normal people. Because of its clinical significance and prognosis is unclear, it is named clonal hematopoiesis of indeterminate potential(CHIP), which has been detected in blood diseases such as myelodysplastic syndrome and lymphoma, and proven to be related to poor prognosis. Recently, CHIP has been also detected in patients with multiple myeloma (MM). In this article, the definition and influencing factors of CHIP, clinical significance, prognosis and treatment in MM were reviewed.